Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Steve Ledger, Serina's Interim CEO, will present on September 11, 2024, at 12:00 p.m. ET.
Serina is known for developing its proprietary POZ Platform™ drug delivery technology. Investors and interested parties can access a live webcast of the presentation through the Investor section of Serina's website. An archived replay will also be available for a time after the event.
This presentation offers an opportunity for Serina to showcase its innovative technology and progress to a global investment audience, potentially impacting its stock performance and investor interest.
Serina Therapeutics (NYSE American: SER), un'azienda biotech in fase clinica, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti di H.C. Wainwright. Steve Ledger, CEO ad interim di Serina, presenterà il 11 settembre 2024, alle 12:00 p.m. ET.
Serina è conosciuta per lo sviluppo della sua tecnologia proprietaria di consegna di farmaci POZ Platform™. Gli investitori e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Investitori del sito web di Serina. Un video registrato sarà anche disponibile per un certo periodo dopo l'evento.
Questa presentazione offre l'opportunità a Serina di mostrare la sua tecnologia innovativa e i progressi a un pubblico globale di investitori, potenzialmente influenzando le sue performance azionarie e l'interesse degli investitori.
Serina Therapeutics (NYSE American: SER), una empresa biotecnológica en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión de H.C. Wainwright. Steve Ledger, CEO interino de Serina, presentará el 11 de septiembre de 2024, a las 12:00 p.m. ET.
Serina es conocida por desarrollar su tecnología de entrega de medicamentos propietaria llamada POZ Platform™. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Inversores en el sitio web de Serina. También estará disponible una repetición archivada durante un tiempo después del evento.
Esta presentación ofrece a Serina la oportunidad de mostrar su tecnología innovadora y avances a una audiencia global de inversión, lo que puede impactar su rendimiento accionarial e interés de los inversores.
세리나 테라퓨틱스 (NYSE American: SER), 임상 단계의 생명공학 회사가 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 스티브 레저, 세리나의 임시 CEO는 2024년 9월 11일 오후 12시(ET)에 발표할 예정입니다.
세리나는 독자적인 POZ Platform™ 약물 전달 기술을 개발한 것으로 알려져 있습니다. 투자자 및 이해관계자는 세리나 웹사이트의 투자자 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 또한 행사 후 일정 기간 동안 기록된 재방송도 제공됩니다.
이번 발표는 세리나가 혁신적인 기술과 진행 상황을 전 세계 투자 청중에게 보여줄 수 있는 기회를 제공하며, 이는 주식 성과와 투자자 관심에 영향을 미칠 수 있습니다.
Serina Therapeutics (NYSE American: SER), une entreprise biotech en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright. Steve Ledger, PDG intérimaire de Serina, présentera le 11 septembre 2024 à 12h00 ET.
Serina est connue pour développer sa technologie de livraison de médicaments propriétaire POZ Platform™. Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section Investisseurs du site web de Serina. Une rediffusion archivées sera également disponible pendant une certaine période après l'événement.
Cette présentation offre à Serina l'opportunité de mettre en avant sa technologie innovante et ses avancées devant un public d'investissement mondial, ce qui pourrait potentiellement influencer ses performances boursières et l'intérêt des investisseurs.
Serina Therapeutics (NYSE American: SER), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Steve Ledger, Interim-CEO von Serina, wird am 11. September 2024 um 12:00 Uhr ET präsentieren.
Serina ist bekannt für die Entwicklung ihrer proprietären POZ Platform™ Arzneimittelabgabetechnologie. Investoren und Interessierte können über den Investor-Bereich der Serina-Website auf ein Live-Webcast der Präsentation zugreifen. Eine archivierte Wiederholung wird außerdem für eine Zeit nach der Veranstaltung verfügbar sein.
Diese Präsentation bietet Serina die Möglichkeit, ihre innovative Technologie und Fortschritte einem globalen Investorenpublikum zu präsentieren, was potenziell die Aktienperformance und das Interesse der Investoren beeinflussen könnte.
- None.
- None.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET.
A live webcast of the presentation can be accessed from the Investor section of Serina’s website, where an archived replay of the event will also be available for a limited time.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.
For inquiries, please contact:
Investor.relations@serinatherapeutics.com
(256) 327-9630
FAQ
When is Serina Therapeutics (SER) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Serina Therapeutics (SER) at the investment conference?
How can investors access Serina Therapeutics' (SER) presentation at the conference?
What is Serina Therapeutics' (SER) main focus in drug development?
What is Serina Therapeutics' (SER) stock symbol and exchange?
